Evaluation of KiSS1 as a Prognostic Biomarker in North Indian Breast Cancer Cases

Singh, Rajani; Bhatt, Madan Lal Brahma; Singh, Saurabh; Kumar, Vijay; Goel, Madhu Mati; Kumar, Rajendra

doi:10.7314/apjcp.2016.17.4.1789

Cited by 11 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical research, also found that the levels of KISS1 were raised in breast cancer. The lesser elevation of KISS1 expression was negative prognosis for overall survival, metastatic propensity, axillary lymph node status, advancing grade, and advancing tumor stage of breast cancer patient [29]. For the breast cancer, KISS1 might act as prognosis biomarker.…”

Section: Discussionmentioning

confidence: 91%

CDCA2 promotes breast cancer progression by downregulating KISS1 expression

2024

EJGO

View full text Add to dashboard Cite

Breast cancer is a females' prevalent malignancy, resulting in higher mortality rates than other cancers. Therefore, exploring effective therapeutic targets and diagnostic biomarkers is critical for improving drugs' curative effect in treating breast cancer patients. The MDA-MB-231 and Michigan Cancer Foundation-7 (MCF-7) cells were transfected by pc-CDCA2, Small interfering RNA Negative Control (siNC), siCDCA2, and pc-KISS1 to investigate the effects of cell division cycle associated 2 (CDCA2) and kisspeptin 1 (KISS1) protein on breast cancer cell's viability, migration and invasion. Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) was used to examine the CDCA2 mRNA expression. Impact of CDCA2 and KISS1 on invasion ability, motility and viability of breast cancer cells were detected via colony-forming unit, Cell Counting Kit-8 (CCK-8) and transwell assay. The Annexin V-Fluorescein Isothiocyanate (annexin V-FITC) staining was employed to determine the cellular apoptosis ratio based on flow cytometry. Findings indicated that CDCA2 expression got increased in breast cancer tissues, which greatly enhanced the cell proliferation, migration and invasion ability. Moreover, the regulation of CDCA2 may suppress the activation of KISS1 in breast cancer cells. In summary, the findings depicted that in breast cancer cells, the CDCA2 expression was enhanced to promote cells motility, invasiveness and viability through inhibition of KISS1 expression. Therefore, targeted gene therapy to suppress the expression levels of CDCA2 and upregulation of the KISS1 have the potential to be promising therapeutic strategies for treating breast cancer metastasis.

show abstract

Section: Discussionmentioning

confidence: 91%

CDCA2 promotes breast cancer progression by downregulating KISS1 expression

2024

EJGO

View full text Add to dashboard Cite

show abstract

“…This reveals the effect of different tumor environments on the action of this gene (e.g., steroidal milieu and the presence or absence of other signaling molecules that might facilitate suppressor or promoter pathways) [22]. KISS1 expression was found to be low in patients with distant metastasis of breast cancer and hepatocellular carcinoma [23,24].…”

Section: Introductionmentioning

confidence: 95%

Association of polymorphisms in metastasis suppressor genes NME1 and KISS1 with breast cancer development and metastasis

Antar

Mokhtar

elghaffar

et al. 2020

J Egypt Natl Canc Inst

View full text Add to dashboard Cite

Background NME1 and KISS1 genes are two tumor metastasis suppressor genes, mapped to chromosomes 17q21.3 and 1q32 respectively. Here, we analyzed the association of EcoR1 (rs34214448—G/T) polymorphism in NME1 gene and 9 del T (rs5780218—A/-) polymorphism in KISS1 gene with breast cancer development and metastasis. Results The study included 75 women newly diagnosed with breast cancer recruited from Oncology Center at Mansoura University Hospitals and 37 age-matched healthy female volunteers as a control group. DNA was extracted from peripheral blood samples and genotyping of rs34214448 and rs5780218 SNPs was carried out by PCR-RFLP technique. NME1 EcoR1 (rs34214448) polymorphism has a statistically significant association with breast cancer risk (P < 0.001). Most of breast cancer group (55%) had heterozygous (G/T) genotype while most of control group (95%) had homozygous wild (G/G) genotype (P < 0.0005). Also, KISS1 rs5780218 polymorphism has a statistically significant association with breast cancer risk. The wild (A/A) genotype was associated with lower risk of breast cancer (A/- + -/- vs. A/A: OR = 3.1, 95% CI = 1.15–8.36, P = 0.025). EcoR1 (rs34214448) polymorphism revealed a significant association with tumor stage and distant metastasis as patients. Carriers of the wild (G/G) genotype were more likely to present with advanced disease stages and distant metastasis. Conclusions Both EcoR1 (rs34214448) polymorphism of NME1 gene and rs5780218 polymorphism of KISS1 gene revealed significant association with increased risk of breast cancer development. The (G/G) genotype of EcoR1 polymorphism was associated with higher risk of breast cancer metastasis.

show abstract

“…In previous studies, multiple kinds of conventional biomarkers related to early diagnosis and prognosis for breast cancer have been developed, such as uPA [11], Rs/DJ-1 [12], and PAI-1 [13]. And recently, circulating miRNAs [14], serum uPAR [15], KiSS1 [16], CD24 [17] etc. also have been recognized as strongly associated with breast cancer development.…”

Section: Introductionmentioning

confidence: 99%

Identification of ZG16B as a prognostic biomarker in breast cancer

et al. 2020

View full text Add to dashboard Cite

Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn’t been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan–Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.

show abstract

Evaluation of KiSS1 as a Prognostic Biomarker in North Indian Breast Cancer Cases

Cited by 11 publications

References 34 publications

CDCA2 promotes breast cancer progression by downregulating KISS1 expression

CDCA2 promotes breast cancer progression by downregulating KISS1 expression

Association of polymorphisms in metastasis suppressor genes NME1 and KISS1 with breast cancer development and metastasis

Identification of ZG16B as a prognostic biomarker in breast cancer

Contact Info

Product

Resources

About